Podcasts about Genotyping

Mark Waters from the Irish Cattle Breeding Federation (ICBF) is on this week's Beef Edge podcast to discuss the National Genotyping Programme which has recently opened for applications. The National Genotyping Programme is a collaborative initiative enabling Ireland to take the first step in achieving a fully genotyped national herd, based on a cost-sharing model between the Department of Agriculture, Food & the Marine, the beef and dairy industry and participating farmers.  Genotyping the national herd will provide a huge opportunity for both the dairy and beef industry to accelerate the rates of gain of our national breeding indexes (e.g. EBI, Eurostar & DBI), which will enhance farm sustainability & reduce carbon emissions. Mark outlines a number of benefits including:-       Labour-saving - farmers who sign up to the NGP will have exclusive access to Double Tissue Tags. By sampling animals at birth, farmers don't have to wait for button tags or hair-cards for SCEP or Pedigree Societies and then round up and bring in animals for sampling at a later stage. It is also much safer and easier to tag and sample newborn animals than more mature animals-       Cost - herds accepted into the National Genotyping Programme will genotype any remaining ungenotyped breeding stock FREE. From 2024 to 2027 (inclusive), farmers will be required to genotype ALL calves born at a reduced cost of approximately €6. (This is an estimate and includes the farmer's contribution of €4 towards genotyping, plus the additional cost associated with a double tissue tag and postage cost.). Herds participating in SCEP will only incur the €6/calf cost of those calves not counted towards their annual 70% SCEP genotyping requirement-       Parent verification - parentage errors (which currently sit at an average of 15% nationally) lead to incorrect Eurostar figures and create paperwork to correct once the animal is already registered. Genotyping at birth will confirm parentage & correct any errors before registration-       Genomic Eurostar figures - animals sampled at birth will receive genomic evaluations at the earliest possible opportunity, thereby increasing the reliability of their Eurostar figures well before they are selected or sold for breeding and confirming their eligibility for SCEP-       Commercial Beef Value (CBV) - genotyped weanlings and store cattle that are being traded through marts will have their CBV displayed on mart screens. Further information is available at: https://www.icbf.com/national-genotyping-programme/ Or contact the ICBF on email: query@icbf.com or phone: 023-8820452 For more episodes from the Beef Edge podcast, visit the show page at:https://www.teagasc.ie/thebeefedge Produced on behalf of Teagasc by LastCastMedia.com 

ICBF business analysts, Mark Waters and Gearoid Slattery, join James Dunne on this week's Dairy Edge to discuss the National Genotyping Programme, how it has performed to date, the benefits of genotyping, some the challenges that have been faced and the opportunity for new participants in the next phase of the programme.    We are also joined by Cork dairy farmer Sheena Murphy who outlines her experience of being in the programme and how it has benefited her herd.Moorepark Open DayThe Teagasc Moorepark Dairy Open Day will take place on Wednesday, 2nd July 2025, 8:30am - 5pm, at the Teagasc Animal & Grassland Research and Innovation Centre, Moorepark, Fermoy, Co. Cork, P61 C996.The theme of this year's event is ‘Innovating for the future'.Join us on Wednesday, 2nd July at Moorepark!For more episodes from the Dairy Edge podcast go to the show page at:https://www.teagasc.ie/animals/dairy/the-dairy-edge-podcast/ The Dairy Edge is a co-production with LastCastMedia.com

ND Corn Seg. Zack Bateson National Genotyping

This week, we chat to Adam on how rewetting plans are going down, to Darren on the upcoming TAMS deadline and Aidan on genotyping lab delays. Aidan also caught up with Tirlán's Bryan Harte on matching early season grass. Hosted on Acast. See acast.com/privacy for more information.

Baby-making is more complicated than it might seem, and any couple struggling to conceive and achieve a successful pregnancy is faced with a confusing maze of fertility optimization measures.This is where whole genome personal genotyping can be very helpful. Your genes obviously have everything to do with fertility, and your genes are unique. Personal genotyping can illuminate what you might be doing wrong in the fertility optimization department. It empowers you and your partner to practice precision Biohacking by identifying the medicine, supplements, therapies, and lifestyle changes you need to bring a beautiful baby into the world.This deep-dive presentation will elucidate 17 problematic fertility genes you may have, how to find them, which conditions they are associated with, and give you a jumping-off point for addressing them...2:45 Important disclaimer: your genes don't have to be your destiny4:00 How to search your genome8:11 Single gene disorders10:18 On procrastination12:57 Polygenetic complexes17:22 MTHFR21:38 SLC19A122:04 DHFR23:25 MTR and MTT26:30 TCN27:00 PAI/SERPINE131:37 PEMT32:38 APEO34:18 FVL and F235:30 NOS37:05 GST/GPX42:04 PON43:20 VDR44:50 Male factor infertility51:40 Stress management hacks57:55 Folic Acid - The New Smoking?59:25 Niacin/Vitamin B31:00:30 Acupuncture1:04:50 Conclusion and inspirationRead: Decode Your Genome with Personal Genotyping for Precision Fertility Optimization

In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation considers how the anticipated approval of a second MASH drug without biopsy might affect clinical trials and discusses two recent publications on patient genotyping and patient clusters. The conversation starts with Roger asking the group whether the presence of two approved MASH medications that do not require biopsy will make recruiting clinical trials that require them more challenging. The group doubts this will not add a significant new challenge to already-challenging trial recruitment. Naim comments that while this is a concern, it is already factored into trial schedules and that, given the number of patients available for trial, this should be highly manageable. Michelle discusses the importance of risk stratification in overall trial enrollment and this issue. Jeff and Mike agree that while this is a concern, it is part of a broader concern about the use of biopsy and should not in itself be a primary focus in terms of trial design at this point in time. Naim introduces two other topics he considers worthy of consideration: the impact of synergy between resmetirom and GLP-1 agonists and the importance of different genetic polymorphisms in predicting the impact of drugs on specific patients. On synergy, he comments that MAESTRO-NASH data suggests that the presence of a GLP-1 does not affect the impact of resmetirom on fibrosis level. On the second point, he notes that several papers looked at major genotypes like PNPLA3 and HD17N13 and specifically cites a late-breaker from Arun Sanyal indicating that g-allele status may impact MASH independent of weight or insulin. Michelle mentions a recent paper in Nature identifying distinct clusters of patients based on how their SLDs progress over time, with a two-cluster solution indicating patients with concomitant diabetes and obesity vs. those without these two concomitant diseases. Roger shares a key point from each paper on treatment in the US. Data in the PNPLA3 paper might suggest that the course of disease in Hispanics, who have high levels of g-allele abnormalities, might be different from other ethnic groups with far lower abnormality rates. He also notes that the faster disease progression in the non-metabolic cluster highlights the importance of learning more about Lean MASH and how to treat it, since faster progression of disease suggests later diagnosis and higher morbidity, mortality and treatment costs levels.

In this episode, my guest Dr Kasia Kines and I explore the Epstein-Barr virus (EBV), a common yet often misunderstood virus that affects a significant portion of the global population. Dr. Kasia Kines is an Amazon best-selling author of the Epstein-Barr Virus Solution, a Doctor of Clinical Nutrition from MUIH (Maryland University of Integrative Health), a graduate of the first doctoral functional nutrition program created by Dr. Liz Lipski, PhD and CEO of Holistic Nutrition Naturally LLC and EBV Educational Institute. Join us as we discuss how EBV is contracted, its symptoms including chronic fatigue, the various factors that can trigger its reactivation, how it can trigger endometriosis and impacts fertility. Dr Kines provide insights and actionable tips to help you manage your health in relation to EBV.   A NUMBER OF ACTIONABLE TIPS WERE DISCUSSED INCLUDING: Recognising personal stressors that may trigger EBV reactivation. Understanding the environmental factors contributing to EBV complications. Importance of proper testing for conditions like Hashimoto's thyroiditis related to EBV. EPISODE HIGHLIGHTS: Understanding Epstein-Barr Virus (EBV): Kasia explains that EBV is a herpes virus affecting 90-95% of the global population and is contracted through various means, including saliva and blood. Triggers for EBV Reactivation: Stress is identified as the primary reactivating trigger for EBV, with personal and environmental factors playing significant roles in its impact on health and fertility. Dioxins and Endometriosis: Kasia discusses how dioxins, which are implicated in endometriosis, can reactivate EBV, highlighting the importance of being aware of environmental toxins. Testing for Autoimmune Conditions: The conversation emphasises the need for proper testing for conditions like Hashimoto's thyroiditis, which often goes unrecognized in women with low thyroid symptoms. Chronic Fatigue and EBV: Kasia shares insights on the connection between chronic fatigue syndrome and EBV, noting that many individuals experience a decline in their health after an initial EBV infection. Importance of Holistic Approaches: The discussion touches on the need for a comprehensive understanding of health that includes emotional, environmental, and physiological factors affecting recovery from EBV. RESOURCES MENTIONED: Epstein-Barr Virus Solution Book: A comprehensive best-selling book by Dr Kines Recent Study on Heavy Metals in Tampons: Highlights concerning findings about contaminants in feminine hygiene products: https://publichealth.berkeley.edu/news-media/research-highlights/first-study-to-measure-toxic-metals-in-tampons-shows-arsenic-and-lead Shearston et al. (2024). Tampons as a source of exposure to metal(oids): https://doi.org/10.1016/j.envint.2024.108849  FURTHER READING: Wang et al., (2024). Evodiamine suppresses endometriosis development induced by early EBV exposure through inhibition of ERβ. Doi: 10.3389/fphar.2024.1426660. PMID: 39148548; PMCID: PMC11324466. Grabarek et al. (2023). Detection and Genotyping of Human Papillomavirus (HPV16/18), Epstein–Barr Virus (EBV), and Human Cytomegalovirus (HCMV) in Endometrial Endometroid and Ovarian Cancers. https://www.mdpi.com/2076-0817/12/3/397# >>Endo Fertility Podcast Goodie Bag

In September 2022, a cell-free DNA assay using next-generation sequencing and quantitative counting tech for fetal antigen status determination became clinically available in the USA. This allowed maternal screening for fetal RBC genotypes for RH negative patients. This test was recognized by thre ACOG in March 2024 as one option to “triage” anti-D immunoglobulin in RH negative women. But can this technology be trusted in alloimmunized patients? In women with antibodies against foreign antibodies, this cell free DNA fetal screening option MUST get it right. We now have that data. In this episode, we will summarize remarkable results, published ahead of print on July 25, 2024 in the Green Journal. This study is a win for science and prenatal care. Listen in for details (BillontoOne, Inc is not a sponsor for this podcast).

Personal genotyping is a Biohacking gamechanger. It gives you an ocean of actionable data about yourself - what kind of diet is ideal for you, how much coffee you should be drinking, how much Vitamin D you need to supplement, which vices you can flirt with and which you must absolutely avoid, if you should do endurance or power training in the gym, etc. And it lets you know which kind of life-ruining genetic conditions you might need a prevention plan for to enjoy a long life of beauty, joy, and meaning.Personal genotyping gets complicated fast, so I recently read the book on personal genotyping, Outsmart Your Genes by Dr. Brandon Colby, and I learned some things about the common mistakes health-conscious, prevention-minded people make when it comes to personal genotyping. These are high-stakes mistakes with perhaps the ultimate consequence if you end up misinformed by the genotyping results you get.Read Review

To watch this as a video Download it and play it from the Downloads section in the Castbox app on your device.Personal genotyping is a Biohacking gamechanger. It gives you an ocean of actionable data about yourself - what kind of diet is ideal for you, how much coffee you should be drinking, how much Vitamin D you need to supplement, which vices you can flirt with and which you must absolutely avoid, if you should do endurance or power training in the gym, etc. And it lets you know which kind of life-ruining genetic conditions you might need a prevention plan for to enjoy a long life of beauty, joy, and meaning.Personal genotyping gets complicated fast, so I recently read the book on personal genotyping, Outsmart Your Genes by Dr. Brandon Colby, and I learned some things about the common mistakes health-conscious, prevention-minded people make when it comes to personal genotyping. These are high-stakes mistakes with perhaps the ultimate consequence if you end up misinformed by the genotyping results you get.Read Review

Proving that our podcast tagline, “Medicine Moves Fast” is true… this episode highlights something that is, once again,

In this episode, the team from the Atrium Health System discuss their award-winning submission to the ASHP Best Practices.  They will share how their program implemented a novel pharmacist-led DPYD testing program with CDS integration and demonstrated pre-treatment testing with genotype-guided fluoropyrimidine dosing improves patient safety by mitigating severe toxicities and hospitalizations in DPYD variant carriers. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Zack Bateson is the Research Manager at the National Ag Genotyping Center based in Fargo, North Dakota. You heard a little bit about the work the National Genotyping Center is doing in episode five with Dr. Brian Jenks. In this episode we dive deeper into the services they offer to provide DNA testing for farmers and agronomists. Bateson got his start in DNA-based testing working in wildlife biology with prairie chickens and lizards, but says all of the skills can be applied to any organisms including variety detection, herbicide resistance, and soil pathogens, which is where he focuses today. “Growers can send us kochia and we can genotype them for the resistance to group 14. Then they're able to have a discussion with either their agronomists or other consultants to see whether it can be another actionable spraying opportunity or if there's something else that they can do about these resistant weeds.” - Zach BatesonThe National Ag Genotyping Center is a private nonprofit diagnostic lab that provides genetic testing to identify pathogens, pests and genetic traits such as resistance to herbicides. This valuable information can help growers determine next steps in treatment of fields without having to rely solely on potentially costly trial and error practices. Alongside these established practices they are also developing identification testing for different causes of root rot.“The work involved is simpler for a person to do, especially with robotics, we can not only do tens of samples per day, but we can extract from hundreds of samples per day. We can test for multiple genetic markers throughout the day, so we're talking hundreds and almost thousands of data points that can be processed and reported out.” - Zach BatesonThis Week on Growing Pulse Crops:Meet Zack Bateson, the Research Manager at the National Ag Genotyping Center based in Fargo, North DakotaExplore the work done at the National Ag Genotyping Center and the value they provide growers in North Dakota. Discover the support and research being developed at the National Ag Genotyping Center and the future projects they expect to participate inGrowing Pulse Crops is produced by Dr. Audrey Kalil and hosted by Tim Hammerich of the Future of Agriculture Podcast.

This week, Adam Woods talks about the beef trade, Darren Carty on the opening of the BIC scheme and Aidan Brennan for his opinion around the genotyping and tagging delays.

Charles O'Donnell, Louise Hickey and Aisling O'Brien bring you the biggest stories of the week in Irish agriculture from Agriland, which this week includes:  ·      Genotyping programme changes after passport delays·      Reactors, restrictions and costs all rise for TB programme ·      665 herds identified for illegal burning·      ‘The dairy cow can't pay for everything'·      TD hits out at septic tank grant rolloutDon't forget to rate, review and follow The Farming Week, Agriland's weekly review of Irish agriculture and visit Agriland.ie for more. 

In this episode of Acquisitions Anonymous, Michael and Heather discuss an investment opportunity in a genomic testing , specializing in DNA sequencing and genotyping for mice. Despite their initial unfamiliarity with the technical details, they recognize the company's significant role in pharmaceutical research. They are impressed by its financial performance, noting substantial growth in revenue and EBITDA, along with high margins. The conversation also explores potential barriers to entry, the impact of technological advancements, and the type of buyer suitable for such a specialized business. They conclude that the company's high margins, growth potential, and strategic importance in healthcare and pharmaceuticals make it an attractive investment opportunity, albeit one requiring a buyer to quickly grasp the complexities of the field.Today's deal comes from Axial.  Axial is a trusted deal-sourcing platform serving professional acquirers in the American lower middle market.Thanks to this week's sponsors!Acquisition Lab and their team have been longtime supporters of the pod.Created by Walker Diebel author of Buy Then Build: How to Outsmart the Startup Game, is an accelerator with a highly vetted cohort-based educational and support community for people serious about buying a business.Acquisition Lab exists to help people buy a business and navigate all the complexities of the process, as well as provide a trusted framework, tools, and resources to support you from search to close.If you are serious about buying a business, check out acquisitionlab.com or email the Lab's director Chelsea Wood, chelsea@buythenbuild.com.-------------CloudBookkeeping offers adaptable solutions to businesses that want to focus on growth with a “client service first” approach. They offer a full suite of accounting services, including sophisticated reporting, QuickBooks software solutions, and full-service payroll options. Do you love Acquanon and want to see our smiling faces? Subscribe to our Youtube channel. Do you enjoy our content? Rate our show! Follow us on Twitter @acquanon Learnings about small business acquisitions and operations.

Dr. Corey Watson is an Associate Professor at the University of Louisville. His work focuses on characterising and cataloguing antibody genetic diversity in human and mouse to better understand disease susceptibility and clinical health outcomes. Dr. William Lees is a researcher at University of London. His work focuses on developing Adaptive Immune Receptor (AIR) reference sets for diverse species and the annotation of experimental sequence data. In this episode we talk about the recent work by the Germline Database Working Group of the AIRR-Community. The accuracy of V and J gene segment assignment improves with the quality of the reference germline set. The accurate assignment is critical for characterization of somatic hypermutation. We discuss the challenges in creating a database to hold all relevant and potentially relevant germline information, especially in the light of increased discovery rate through technological advances and improved analysis pipelines. We also reflect on the complexity in handling personalised germline reference sets. The episode is hosted by Dr. Ulrik Stervbo and Dr. Zhaoqing Ding. Comments are welcome to the inbox of onairr@airr-community.org  or on social media under the tag #onAIRR. Further information can be found here: https://www.antibodysociety.org/the-airr-community/airr-c-podcast.  Website of the AIRR-C Germline Database Working Group https://www.antibodysociety.org/the-airr-community/airr-working-groups/germline_database/  Papers mentioned Collins, Andrew M., Mats Ohlin, Martin Corcoran, James M. Heather, Duncan Ralph, Mansun Law, Jesus Martínez-Barnetche, et al. 2023. “AIRR-C Human IG Reference Sets: Curated Sets of Immunoglobulin Heavy and Light Chain Germline Genes.” BioRxiv. https://doi.org/10.1101/2023.09.01.555348  Rodriguez, Oscar L., Yana Safonova, Catherine A. Silver, Kaitlyn Shields, William S. Gibson, Justin T. Kos, David Tieri, et al. 2023. “Genetic Variation in the Immunoglobulin Heavy Chain Locus Shapes the Human Antibody Repertoire.” Nature Communications 14 (1). https://doi.org/10.1038/s41467-023-40070-x  Lees, William D., Scott Christley, Ayelet Peres, Justin T. Kos, Brian Corrie, Duncan Ralph, Felix Breden, et al. 2023. “AIRR Community Curation and Standardised Representation for Immunoglobulin and T Cell Receptor Germline Sets.” Immunoinformatics (Amsterdam, Netherlands) 10 (100025): 100025. https://doi.org/10.1016/j.immuno.2023.100025  Jackson, Katherine J. L., Justin T. Kos, William Lees, William S. Gibson, Melissa Laird Smith, Ayelet Peres, Gur Yaari, et al. 2022. “A BALB/c IGHV Reference Set, Defined by Haplotype Analysis of Long-Read VDJ-C Sequences From F1 (BALB/c x C57BL/6) Mice.” Frontiers in Immunology 13. https://doi.org/10.3389/fimmu.2022.888555  Ford, Easton E., David Tieri, Oscar L. Rodriguez, Nancy J. Francoeur, Juan Soto, Justin T. Kos, Ayelet Peres, et al. 2023. “FLAIRR-Seq: A Method for Single-Molecule Resolution of near Full-Length Antibody H Chain Repertoires.” The Journal of Immunology 210 (10): 1607–19. https://doi.org/10.4049/jimmunol.2200825  Omer, Aviv, Ayelet Peres, Oscar L. Rodriguez, Corey T. Watson, William Lees, Pazit Polak, Andrew M. Collins, and Gur Yaari. 2022. “T Cell Receptor Beta Germline Variability Is Revealed by Inference from Repertoire Data.” Genome Medicine 14 (1). https://doi.org/10.1186/s13073-021-01008-4  Rodriguez, Oscar L., Catherine A. Silver, Kaitlyn Shields, Melissa L. Smith, and Corey T. Watson. 2022. “Targeted Long-Read Sequencing Facilitates Phased Diploid Assembly and Genotyping of the Human T Cell Receptor Alpha, Delta, and Beta Loci.” Cell Genomics 2 (12): 100228. https://doi.org/10.1016/j.xgen.2022.100228  Tools mentioned TIgGER (Immcantation) https://tigger.readthedocs.io/en/stable  IgDiscover https://github.com/NBISweden/IgDiscover  Partis https://github.com/psathyrella/partis MiXCR https://mixcr.com

On this episode Lauren, Claire and Eoin where joined by Mark Waters from ICBF (Irish Cattle Breeding Federation).They have a conversation about the National Genotyping Programme.  The National Genotyping Programme is a collaborative initiative designed to enable Ireland to take the first step in achieving a fully genotyped national herd. The programme has been developed based on a cost-sharing model between the Department of Agriculture, Food & the Marine, the beef & dairy industry & participating farmers.Genotyping the national herd will provide a huge opportunity for the Dairy and Beef industry to increase its sustainability credentials on a global scale. Ireland will become the first country in the world to provide a DNA-verified traceability system. It will lead to an acceleration in the rates of gain of our national breeding indexes (e.g. EBI, Eurostar and DBI), which will enhance farm sustainability and reduce carbon emissions.To find out more; https://www.icbf.com/The Sod Pod; https://ie.timacagro.com/podcast-the-sod-pod/

David Coen from Sheep Ireland is on this week's OviCast to talk about progress in breeding in the hill sector. David discusses the impact hill genetics has on the national flock, SIS scheme and ram eligibility.  We discuss the work by the 17 breeding groups over the past year to get rams genotyped and the impact this has had on developing flock books. Finally we finish up with David discussing how breeders can build on this going forwards to improve genetic improvement in hill flocks. Some links discussed in this week's episode to search for potential rams or to sign up to Sheep Ireland are:Ram Search:https://appsh.sheep.ie/ram-searchRam sales/catalogues:https://www.sheep.ie/?page_id=29Sign up online form:https://forms.office.com/pages/responsepage.aspx?id=AH5m37xZikKh2Tgra-Oid02OFzIK2SJKuUbHvUCuGqJURVpMT1ZLRU02RkxPTDdGTkhFRFNKNFpLTS4uFor more episodes from the OviCast podcast, visit the show page at:https://www.teagasc.ie/animals/sheep/ovicast-sheep-podcast

In this episode, Renslow Sherer, MD, discusses managing virologic failure in a person living with HIV who is heavily treatment experienced, including:Guideline recommendations for selecting a new ART regimenOptions for patients with multidrug-resistant HIV from existing drug classes and novel mechanisms of action with no cross-resistanceData from TMB-301 and TMB-311 for ibalizumab, BRIGHTE for fostemsavir, and CAPELLA for lenacapavir on the use of these agents for people living with HIV who are heavily treatment experienced with multidrug-resistant HIVPresenter:Renslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTo download the slides:https://bit.ly/3OcqxIETo view the full online program:https://bit.ly/3ZjSFhg

In this episode, Renslow Sherer, MD, discusses managing a first ART failure in the setting of COVID-19, including:Guideline recommendations for resistance testingGuideline recommendations for selecting a new ART regimenData on retained efficacy of NRTIs in second-line regimens in the EARNEST and NADIA studiesConsideration of drug‒drug interactions between ART and COVID-19 treatmentPresenter: Renslow Sherer, MDDirector International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois To download the slides: https://bit.ly/3OcqxIE To view the full online program: https://bit.ly/3ZjSFhg

On this week's show, Adam Woods talks about genotyping and SCEP, Darren Carty on the EU's nature restoration law and Aidan Brennan looks forward to Moorepark 2023.

Gearóid Slattery from ICBF joins Catherine Egan on this week's Beef Edge podcast to discuss the National Genotyping Programme.   The National Genotyping Programme is a collaborative initiative enabling Ireland to take the first step in achieving a fully genotyped national herd. The scale of the programme is a world first and sees Ireland placed firmly at the forefront when it comes to national sustainability efforts. The NGP has been developed based on a cost-sharing model between the programme partners, consisting of the Department of Agriculture, Food & the Marine (DAFM), Dairy Industry Ireland (DII), Meat Industry Ireland (MII) and participating farmers.  The first year of the programme will be funded by the Brexit Adjustment Reserve (BAR).  For the remaining four years, the genotyping costs of €18 per sample will be divided equally between the three Programme Partners; 1. DAFM, 2. DII & MII and 3. Participating farmers (i.e. €6 contribution per programme partners). Genotyping the national herd will provide a huge opportunity for both the dairy and beef industry to increase its sustainability credentials on a global scale. Ireland will become the first country in the world to provide a DNA-verified traceability system.  It will lead to an acceleration in the rates of gain of our national breeding indexes (e.g. EBI, Eurostar & DBI), which will enhance farm sustainability and reduce carbon emissions. The closing date for applications for dairy herds is 14th July 2023. The closing date for beef herds is yet to be announced. For more episodes from the Beef Edge podcast, visit the show page at:https://www.teagasc.ie/thebeefedge         Produced on behalf of Teagasc by LastCastMedia.com 

On this week's episode of the Dairy Edge, Mark Waters, Co-ordinator of the DNA Registration Project at ICBF joins Stuart Child to discuss the National Genotyping scheme that was launched recently by the Minister for Agriculture. Mark starts by telling us exactly what genotyping is and what it has to offer both farmers and the industry as a whole.  He says that it is hard to overstate the value of genotyping and that the big thing will be the rate of gain that will be achievable. This has the potential to allow for more palatable actions with regard to climate change targets compared to some of the actions that are currently being suggested, such as a large scale reduction in animal numbers . Mark then explains how farmers can sign up for the scheme, what they have to do in 2023 and what is expected from 2024 onwards when the DNA registration process will start in earnest. Finally, Mark highlights that the purpose of the scheme is to genotype the existing herd to allow for the DNA registration process to become a reality and that people are committing to this when signing up.  It is imperative that people take samples and return them in a timely manner to facilitate preparation for the DNA registration next spring.     For more episodes from the Dairy Edge podcast go to the show page at: https://www.teagasc.ie/animals/dairy/the-dairy-edge-podcast/ The Dairy Edge is a co-production with LastCastMedia.com

This week, we talk to Adam on selling bulls, Darren on the impact of Islamic festivals on lamb prices and Aidan on the new national genotyping programme. Adam also chats to Michael Murray from ESB Networks on the possible dangers during the silage season.

On this week's podcast we discuss the weanling trade, the ash dieback debacle and the new €83m genotyping scheme.

Aisling O'Brien & Francess McDonnell bring you the biggest stories of the week in Irish agriculture, which this week include: - Rewetting controversy continues in Dáil and on the streets - Minister formally announces €43m genotyping programme - Almost 130,000 farmers apply for BISS and other schemes - Green TD calls for live exports to end - Vet issues appeal after 8 calves killed by slurry fumes - Bogs to be developed for recreation activities Rate, review and follow The Farming Week, Agriland's weekly review of Irish agriculture and visit Agriland.ie for more. --- Send in a voice message: https://podcasters.spotify.com/pod/show/the-farming-week/message

We introduce our new co-host, Mr. Jeremy Sherrill! In an interview with Bioinformatician Dr. Abeer Madouly, we discuss the evolving role of race, ethnicity, and ancestry in the field of immunogenetics. Dr. Madouly discusses how and why they are used in HLA genotyping now and in the future. We also answer a question from listener regarding CHS testing in our newest segment, The Tea.

This week we chat to Adam Woods on the new genotyping scheme, Darren Carty on the new Young Farmer scheme and Siobhan Walsh gives her thoughts on how specialised livestock farmers can mix it up with tillage farmers.

In this week's episode we'll discuss how azacytidine therapy influences the contributions of mutated HSC clones to hematopoiesis in MDS and CMML, learn more about the risk of venous thromboembolism in patients with adult-type diffuse glioma, and discuss the importance of 1p32 deletions as an independent and adverse prognostic factor in myeloma.

(01:11)Dr. Hasadsri, could you provide us with an overview of what carrier screening is?(02:28)Can you really expand on why these tests are important?(05:25)So in your experience, who could benefit from carrier screening and when should that testing be performed?(06:45)Can you just share how does a healthcare provider order carrier screening and then secondarily what sample types are accepted?(08:05)Can you share what are some of the unique features of our testing that sets the Mayo Clinic Laboratories apart?(10:36)So the last question I have is could you just summarize the benefits of doing carrier screening at Mayo?

David Coen from Sheep Ireland joins Ciarán Lynch on this week's OviCast to explain genotyping rams.  David outlines the benefits of genotyping rams and the kind of information it can provide from scrapie genotypes to parentage verification to genomic evaluations.  David and Ciarán also discuss the processes and costs involved for producers.  David then explains the ram genotype task in the Proposed DAFM Sheep Improvement Scheme highlighting the criteria for both lowland and hill flocks.  Finally, in relation to hill flocks, David discusses how genotyping could lay the foundation for breed improvement programmes within hill breeds.  For more episodes from the OviCast podcast, visit the show page at:https://www.teagasc.ie/animals/sheep/ovicast-sheep-podcast

NBA great Alonzo Mourning returned home from the Sydney Olympics after winning the gold medal feeling ill. He surprisingly was diagnosed shortly after with kidney disease. Scientists have discovered his type of kidney disease is linked to having genetic variants of the APOL1 gene – ones that 13% of people with African ancestry carry. Dr. Ogo Egbuna leads clinical development for the team researching APOL1-mediated kidney disease at Vertex where they're investigating a small molecule therapy to target its underlying cause.Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.  Featured guests:Alonzo Mourning is a retired NBA player, the Vice President, Player Programs for the Miami Heat, an advocate for kidney disease research, and a beneficiary of a kidney transplant.David Friedman is an Associate Professor of Medicine, Harvard Medical School and a Principal Investigator and Nephrologist at Beth Israel Deaconess Medical Center. He's researched and consulted for Vertex Pharmaceuticals.Janice Lea  is a Professor of Medicine and Clinical Director of Nephrology at Emory University School of Medicine.Ogo Egbuna is Vice President, Clinical Development at Vertex Pharmaceuticals Read more about Vertex's approach to targeting kidney disease.Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.  

The buzz around the potential of Precision Medicine continues as new technologies, more powerful computing and our ability to store, share and interpret Big Data increases.  On this podcast Steve Coldicott and Scott Buckler chat about all aspects of the industry with patients, healthcare industry and research professionals about creating personalised medicines for each and every one of us. Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and side effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.  During this episode, Dr Anthony Khawaja chats with Scott Buckler about the need for precision management in glaucoma.   For more content, and to see many episodes of this podcast in video form, please visit out website: https://precisionmedicineforum.com/

We chat to Adam Woods on why he thinks genotyping is the key to dairy beef success. Declan Marren talks about the key takeaways from the Thrive Open Day in Cashel and we pose key questions on the new nitrate rules to Aidan Brennan.

Host Jeremy C. Park talks with Antonio Taylor, Director of Technical Services for Transnetyx and Marketing Chair for SIM Memphis, who discusses the power of working with youth and introducing and encouraging them to pursue STEM-related professions and possibilities. During the interview, Antonio spotlights his role at Transnetyx, a Memphis, Tennessee area-based business that launched the world's first fully automated genotyping system for detecting transgenic, knockout, knock-in, SNP, and CRISPR mutations in animal research models. Transnetyx's mission is to provide the most efficient path to discovery for researchers across the globe, in order to pave the way for research to advance and deeper understandings to emerge.Antonio then highlights SIM Memphis, which is the Memphis Chapter of the Society for Information Management, a professional society of local IT leaders. He spotlights their efforts around mentoring and working with youth and youth-driven organizations, including Memphis-Shelby County Schools, DeSoto County Schools, Memphis Public Library, and Boys and Girls Clubs of Greater Memphis, in order to promote academic excellence and student success and to introduce and encourage the pursuit of IT and STEM-related professions and possibilities. He wraps up discussing their SIM Strategy Series for Executives, which is Memphis' premier single-day event designed exclusively for the IT executive community being held on October 26, 2022 at the Hilton Memphis Hotel.Visit https://chapter.simnet.org/memphis/home to learn more about SIM Memphis, and https://www.transnetyx.com to learn more about Transnetyx.

In this episode, John D. Baxter, MD, explores recommendations and data on the use of proviral DNA genotyping to inform antiretroviral therapy (ART) choice for patients who are treatment experienced.Listen as he gives his perspectives on:US Department of Health and Human Services guideline recommendations on the use of proviral DNA genotypingUS Department of Health and Human Services guideline recommendations and supporting data on switching ART with viral suppression and underlying drug resistanceStudy 380-4030 on outcomes with bictegravir- and dolutegravir-based ART in patients with preexisting nucleos(t)ide reverse-transcriptase inhibitor resistanceThe BRAAVE 2020 study on switching to bictegravir/emtricitabine/tenofovir alafenamide in Black persons with HIV, some of whom had baseline ART resistanceBetween-class ART switches with underlying resistanceSusceptibility of tenofovir disoproxil fumarate and abacavir with thymidine analogue mutationsPresenter:John D. Baxter, MDProfessor of MedicineDivision of Infectious DiseasesDepartment of PathologyCooper Medical School of Rowan UniversityHead, Division of Infectious DiseasesCooper University Health CareCamden, New JerseyFollow along with the slides at:https://bit.ly/3HmkSLcSee the entire program at: https://bit.ly/3fOl0XX

Is sequencing the SARS-CoV-2 genome useful for patient care? What about institutional infection control? And if clinical labs decide to perform SARS-CoV-2 sequencing, how should they do it? How should they report the results? And will they get paid? Until recently, sequencing of SARS-CoV-2 genomes has mainly been done in public health or research laboratories. Now, there is increasing interest in sequencing the viral genome in healthcare settings for uses in patient care and infection control. We'll be talking about a new guideline that can help clinical labs and institutions decide whether to perform SARS-CoV-2 sequencing. Guest: Dr. Alex Greninger Dr. Francesca Lee Links: Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping: an IDSA/ASM Consensus Review Document https://journals.asm.org/doi/10.1128/JCM.01659-21

Host: Matt Birnholz, MD Guest: Mark H. Stoler, MD Now that vaccinated women have entered the screening population, we are seeing HPV 16 and 18 decreasing. These changes in HPV genotype prevalence may have a significant impact on the clinical management of cervical cancer, and an HPV test with extended genotyping may change the way we screen for cervical cancer as well. Joining Dr. Matt Birnholz to discuss the role of HPV extended genotyping in cervical cancer screening and the importance of identifying HPV 31 is Dr. Mark Stoler, Professor of Pathology and Clinical Gynecology at the University of Virginia Health System.

In this episode of MODPATH CHAT, our guests Dr. Natalia Buza and Dr. Pei Hui from the department of Pathology at Yale University share their approach to the application of DNA genotyping to the diagnosis and prognostication of Hydatidiform moles and Gestational trophoblastic tumors. Genotyping is now the gold standard in the confirmation and subtyping of sporadic hydatidiform moles. DNA genotyping is critical to the separation of gestational trophoblastic neoplasia from non-gestational counterparts/mimics of either germ cell or somatic origin. Modern Pathology, 34, 1658–1672 (2021). https://www.nature.com/articles/s41379-021-00831-9. See acast.com/privacy for privacy and opt-out information.

In this week's episode, we'll start by reviewing an intriguing study that, while not randomized, calls into question whether less-intensive induction therapies provide a survival or quality of life benefit in older patients with AML. Next, we will review the somewhat surprising findings from human and mouse model studies demonstrating that platelets downregulate T cell activity during sepsis, a finding that is associated with reduced survival. We will close with a report on a targeted genotyping approach that could reduce diagnostic and treatment delays in patients with primary CNS lymphoma.

With the rams sales season kicking into high gear, Dr Alan Bohan from Sheep Ireland joins Ciarán Lynch on this week's OviCast to discuss how genotyping has improved the genetic information available to breeders and farmers alike. Alan discusses the increase in the number of animals genotyped this year and explains the process and costs involved in genotyping. He then discusses the benefits of genotyping animals from parentage verification to scrapie genotyping. Genotyping also provides a genomic evaluation which improves the accuracy of the index and Alan explains why this is a major benefit to farmers. Finally, he discusses this year's Sheep Ireland multi-breed sale and the use of the ram search tool to find rams and pedigree breeders in your own locality. For more episodes from the OviCast podcast, visit the show page at: https://www.teagasc.ie/animals/sheep/ovicast-sheep-podcast

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Anna-Barbara Moscicki, MD Updated cervical cancer screening guidelines were published by both the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS). Dr. Lee Shulman leads a discussion with Dr. Anna-Barbara Moscicki on the recent guidelines, the range of cervical cancer screening tests, and the impact on risk stratification and patient management.

CME credits: 0.25 Valid until: 14-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/riding-wave-change-cervical-cancer-screening-managing-patients-light-risk-using-extended-genotyping/12697/ Updated cervical cancer screening guidelines were published by both the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS). Dr. Lee Shulman leads a discussion with Dr. Anna-Barbara Moscicki on the recent guidelines, the range of cervical cancer screening tests, and the impact on risk stratification and patient management.

CME credits: 0.25 Valid until: 14-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/riding-wave-change-cervical-cancer-screening-managing-patients-light-risk-using-extended-genotyping/12697/ Updated cervical cancer screening guidelines were published by both the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS). Dr. Lee Shulman leads a discussion with Dr. Anna-Barbara Moscicki on the recent guidelines, the range of cervical cancer screening tests, and the impact on risk stratification and patient management.

Genotyping for COVID-19 variants surveillance is explored with the Director of the UC Davis Genome Center and the director of the Healthy Davis Together project.

Read the article on Wiley Online Library: https://onlinelibrary.wiley.com/doi/10.1111/trf.16100

An awesome interview with Lauren McKnight from the Garvan Institute on all things genetic sequencing, profiling and genotyping.  Covering the following key point: Investigate the use of technologies to determine inheritance patterns in a population using, for example: (ACSBL064, ACSBL085) - DNA sequencing and profiling (ACSBL086) Thanks to STEM Reactor for sponsoring this podcast. They provide everything you need to do biotechnology at school, check them out at www.stemreactor.com.au

Dr Janjira Thaipadungpanit from our MORU unit in Bangkok, Thailand, tells us about her research on molecular diagnosis and bacterial genotyping A molecular microbiologist, Dr Janjira's research focusses on using bacterial typing based on genome to confirm which disease is present in a patient. She aims to develop a single whole genome sequence type test using mutliple-PCR assays that can determine from a single sample of blood what bacteria or viruses are present in a patient's blood – thereby speeding up diagnosis and potentially saving lives in resource-limited settings. Head of Molecular Microbiology at MORU, Dr Janjira Thaipadungpanit's research interests include the molecular epidemiology of leptospirosis and melioidosis using multilocus sequence typing or genome data and molecular diagnosis to identify the causes of acute febrile illness and sepsis in patients.